Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
WALTHAM, Mass., April 12, 2016 -- Radius Health (Nasdaq:RDUS) announced today that it will release its first quarter 2016 financial results on Thursday, May 5, 2016.
In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Thursday, May 5, 2016 to discuss the results and provide a company update.
Conference Call Information:
Date: Thursday, May 5, 2016
Time: 8:00 a.m. ET
Domestic Dial-in Number: 1-877-705-6003
International Dial-in Number: 1-201-493-6725
Live webcast: http://public.viavid.com/index.php?id=119098
For those unable to participate in the conference call or webcast, a replay will be available beginning May 5, 2016 at 10:30 a.m. ET until May 19, 2016 at 11:59 p.m. ET. To access the replay, dial 1-877-870-5176 or 1-858-384-5517. The replay pin number is 13635038.
A live audio webcast of the call will also be available on the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will be available for 14 days on the Radius website, www.radiuspharm.com. The full text of the announcement and financial results will also be available on the Company's website.
About Radius
Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Radius’ Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe and a New Drug Application (NDA) was submitted in the U.S. at the end of the first quarter of 2016. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in multiple applications including cancer.
CONTACT: Investor Relations Barbara Ryan 203-274-2825 [email protected] Media Lori Gorski 617-551-4096 [email protected]
